Abstract: The  prognosis of fundus neovascular diseases mainly depend on the situation of the neovascularization. vascular endothelial growth factor (VEGF) is considered to be the most important pathogenic factor, and also an important therapeutic target in fundus neovascular diseases.  Aflibercept is the latest generation of antiVEGF drugs, which binds VEGFA and VEGF\|B, as well as plateletderived growth factor (PDGF), has higher affinity with VEGF. Aflibercept is applied to the treatment of wet agerelated macular degeneration, retinal vein occlusion, diabetic retinopathy and polypoidal choroidal vasculopathy. It can improve the  best corrected visual acuity and reduce the central retinal thickness. At the same time, in some nonresponse cases the good results are also received.